Trial Profile
A pilot study of combination therapy with VELCADE [bortezomib], doxil [doxorubicin liposomal], and dexamethasone (VDd) in multiple myeloma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2019
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Doxorubicin liposomal (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 06 Feb 2012 Actual end date (Dec 2007) added as reported by ClinicalTrials.gov.
- 06 Feb 2012 Actual end date (Dec 2007) added as reported by ClinicalTrials.gov.
- 06 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.